BACKGROUND: In the current national debate regarding private insurance versus Medicaid expansion, understanding how insurance is associated with racial disparities in prostate cancer (CaP) outcomes has broad policy implications. In the current study, the authors examined the association between insurance status, race, and CaP outcomes. METHODS: The Surveillance, Epidemiology, and End Results program identified 155,524 men aged < 65 years who were diagnosed with CaP from 2007 through 2014. The association between insurance and stage of disease at the time of presentation was examined. Among men with localized CaP, the associations between insurance and receipt of therapy and prostate cancer-specific mortality (PCSM) were determined. RESULTS: Compared with private insurance, men with Medicaid were more likely to present with metastatic disease (adjusted odds ratio [AOR], 4.27; 95% confidence interval [95% CI], 4.01-4.55), were less likely to receive definitive treatment (AOR, 0.67; 95% CI, 0.62-0.71), and had increased PCSM (adjusted hazard ratio, 1.83; 95% CI, 1.50-2.24), regardless of race. Significant interactions between race and insurance status indicated that insurance had more than an additive association with race. Among privately insured patients, disparities in PCSM (AOR, 1.2; 95% CI, 1.03-1.40 [P 5.019]) and presentation with metastatic disease (AOR, 1.13; 95% CI, 1.06-1.21 [P<.001]) were observed. No disparities were observed among patients with Medicaid insurance with regard to PCSM (AOR, 0.79; 95% CI, 0.52-1.20 [P 5.272]) and metastatic disease (AOR, 0.91; 95% CI, 0.80-1.03 [P 5.139]). CONCLUSIONS: Racial disparities in the outcomes of patients with CaP were observed in privately insured cohorts, whereas these disparities appeared to be reduced among patients with Medicaid insurance. However, outcomes need to be improved overall. Whether the equality in outcomes for Medicaid is due to white and African American patients doing "equally poorly" or "equally well" is unclear. Cancer 2018;124:752-9.
INTRODUCTION
Prostate cancer (CaP) represents the most common non-skin cancer diagnosed in men. In 2017, there will be an estimated 161,360 new cases and 26,730 deaths. 1 It is well known that African American patients have disparate outcomes from CaP. Although part of the greater CaP mortality in African American men is due to more aggressive disease at the time of presentation, there also are disparities in how care is accessed and delivered, [2] [3] [4] [5] [6] [7] [8] potentially worsening already unequal outcomes. Therefore, it is critical that we examine the modifiable factors that are associated with disparate outcomes in patients with CaP.
The presence and type of health insurance are key factors that may influence CaP outcomes. How to increase health insurance coverage of the uninsured is a continuing national debate, and Medicaid plays a large role in insuring underserved individuals. The Patient Protection and Affordable Care Act (ACA) was signed into law in March 2010 with the expectation of increasing Medicaid enrollment by 15 million beneficiaries. 9 As expansions of the ACA have helped bring the number of uninsured Americans to an all-time low, and as the expansion or nonexpansion of Medicaid (vs subsidizing private insurance) has become a politically charged issue, it is critically important to evaluate the relationship Medicaid (vs private insurance) may have on treatment patterns in the care of patients with CaP.
MATERIALS AND METHODS

Patient Population and Study Design
Sponsored by the National Cancer Institute, the Surveillance, Epidemiology, and End Results (SEER) program collects and publishes cancer incidence, survival, and treatment data from population-based cancer registries; SEER captures approximately 98% of incident cancers and the 18 tumor registries encompass nearly 30% of the US population. 10 The SEER program was used to identify 155,524 men aged < 65 years with known insurance status who were diagnosed with CaP from 2007 through 2014. Patients were excluded if they had metastatic disease (5469 patients, although these individuals were included for secondary endpoint analysis of presentation with metastatic disease), missing Gleason score (1641 patients), or missing T classification (333 patients), as shown in Supporting Information Figure 1 . The primary independent variables of interest in the current study were race and insurance status. Race was classified as either African American, white, or other as provided by SEER. 10 We defined insurance status as nonMedicaid, Medicaid, or uninsured if the patient was classified by SEER as "insured" or "insured/no specifics," as "any Medicaid," or as "uninsured," respectively. SEER defines "insured" as patients with Medicare insurance, non-Medicaid insurance, and insurance coverage from the military or Veterans Affairs at the time of initial diagnosis, treatment, or both. The study population was limited to patients aged <65 years because SEER recommends exercising caution when using the insurance status variable among patients aged >65 years given that many who are classified as "uninsured" are Medicare eligible. The inclusion period was limited to 2007 through 2014 because 2007 represents the year that data regarding insurance status were introduced and 2014 represents the most recent year for which full information is available.
Gleason scores, as provided by the SEER program, represent the highest Gleason score identified at the time of surgery or biopsy (for nonsurgically managed patients). Stage of disease was determined using the sixth edition of the American Joint Committee on Cancer staging system as provided by the SEER program. 10 Definitive treatment was classified according to the National Comprehensive Cancer Network guidelines and included radical prostatectomy, external beam radiotherapy, brachytherapy, or any combination thereof.
11
Median household income and educational status (percentage of residents aged >25 years with at least a high school education) were determined at the county level by linking to the 2000 US Census and were treated as continuous variables. 12 
Statistical Analyses
Baseline clinical and demographic characteristics were compared using one-way analysis of variance (Table 1) . Multivariable logistic regression modeled the unadjusted and adjusted associations between insurance coverage and the presentation of metastatic disease; men were only included if they had data available regarding the covariates of interest (155,524 patients, 115,838 of whom were white and 29,975 of whom were African American). Among men with localized CaP, 11, 13 the associations between insurance status and receipt of definitive treatment (144,612 patients) and prostate cancer-specific mortality (PCSM) (142,988 patients) were determined using multivariable logistic and Fine and Gray competing risks regression models, respectively.
14 Interaction models for race and Medicaid also were applied for all aforementioned outcome measures. The multivariable analysis for the endpoint of presentation of metastatic disease was adjusted for the demographics of age, race, income, and education (Table 2) . Similarly, the multivariable logistic regression analysis for the receipt of definitive treatment among men with localized disease was adjusted for age, race, income, education, Gleason score, and stage of disease (Table 3) . Prostate-specific antigen (PSA) was not included in the primary analyses because of concerns regarding its accuracy as recorded in SEER. Because SEER has audited and corrected PSA data, the analyses were repeated to include these PSA data (see Supporting  Information Tables (1-5 )), with PSA levels of <10 ng/ mL, 10 to 20 ng/mL, and >20 ng/mL corresponding to low-risk, intermediate-risk, and high-risk CaP, respectively, according to National Comprehensive Cancer Original Article
Network guidelines. The Fine and Gray competing risk regression multivariable model for the endpoint of PCSM was adjusted for the aforementioned covariates in addition to receipt of definitive treatment (Table 4) . We then evaluated whether there was a statistical interaction between insurance status and race with respect to presentation with metastatic disease (Table 5) , the use of definitive treatment (Table 6) , and PCSM (Table 7) . To better understand temporal trends of insurance status from 2007 through 2014, age-adjusted rates and annual percent changes were calculated using the Joinpoint Regression Program (version 4.3.1.0) 15 . All tests of statistical significance were 2-sided. A threshold of .05 for P values was used to determine statistical significance. Statistical analyses were performed using STATA statistical software (version 13.0; StataCorp LLC, College Station, Texas).
RESULTS
Men with Medicaid insurance presented with metastatic disease at a higher rate compared with men with private, other, or no insurance ( A significant interaction between race and the type of insurance coverage was found for the outcomes of presentation with metastatic disease (P for interaction 5 .006) ( Table 5) , receipt of definitive treatment (P for interaction 5 .010) (Table 6 ), and PCSM (P for interaction 5 .032) ( (Table 6 ). It is interesting to note that cumulative incidence plots of PCSM demonstrated that when projected out to 100-month follow-up, rates of PCSM were much greater for black versus nonblack men among those with private insurance (Fig. 1) , whereas racial disparities were reduced in patients with Medicaid insurance, with a trend toward higher rates of PCSM overall (Fig. 2) .
Temporal trends in insurance status were further analyzed (see Supporting Information Fig. 2 ) to assess changes to insurance distribution among patients aged <65 years between 2007 and 2014. Among all patients classified by SEER as having or not having insurance, we found that the slope of rates for patients diagnosed with any cancer and CaP statistically increased by 4.2% (95% CI, 2.9%-5.5%) and 2.4% (95% CI, -0.1% to 5.0%) per year with Medicaid insurance, whereas rates for patients with private insurance statistically decreased by 1.8% (95% CI, -2.2% to -1.5%) and 12.6% (95% CI, -16.5% to -8.5%), respectively, per year since 2011. For patients with metastatic CaP at the time of presentation, the slope of rates for those with Medicaid and private insurance were noted to have decreased by 1.6% (95% CI, -4.3% to 1.2%) and 7.0% (95% CI, -10.2% to -3.8%), respectively, per year.
DISCUSSION
Medicaid coverage was found to reduce disparities in CaP mortality and metastatic disease between white and African American patients compared with private insurance. At the same time, outcomes for all men overall were worse for patients with Medicaid compared with those with private insurance. Thus, although Medicaid appeared to promote equality in CaP outcomes, these outcomes overall were worse than those for patients with private insurance.
The current study has critical implications for CaP care because there is ongoing uncertainty in the US health care system. Under the ACA, Medicaid expanded health care coverage to those individuals who previously were uninsured, a patient population largely comprised of minorities and/or patients from counties of lower household incomes and educational levels, 3 and this expansion has been hypothesized to reduce racial and socioeconomic inequalities in health care. [16] [17] [18] The results of the current study support this hypothesis.
Previous studies investigating CaP outcomes have shown that insurance coverage is associated with improved access to cancer care, earlier detection, lower disease burden, increased quality of life, and improved cancer-specific outcomes. [19] [20] [21] The literature has clearly demonstrated that increased access to insurance is an important factor in equal access to care and improved cancer outcomes.
Epidemiologically, the results of the current study demonstrated that African American men with CaP are more likely to present with metastatic disease, less likely to be treated definitively, and more likely to die of their cancer than men of other races, results that are consistent with other findings in the literature that have been persistent over time. [22] [23] [24] [25] [26] [27] Although previous studies have indicated that insurance status is associated with a reduction in racial treatment disparities among men diagnosed with localized CaP, 2,3 we found that racial disparities were only mitigated among men with Medicaid coverage. This appears to be due to factors that we can only hypothesize: perhaps more equal screening, detection of disease, adjuvant care, or posttreatment support is driving the reduced disparate outcomes. Gaps in presentation with metastatic disease, use of definitive treatment, and PCSM were observed among privately insured patients, perhaps indicating that the variability in private health insurance plans leads to disparate health care delivery. In other words, subsidizing private health care without some type of uniform standard may result in a persistence of unequal care, even if the overall number of uninsured patients is reduced. Moreover, the ACA established a marketplace that allowed individuals to purchase coverage without medical underwriting while eliminating cost sharing across most health plans for recommended preventative services, such as cancer screening. In juxtaposition, privately insured patients could be responsible for considerable outof-pocket costs, including plan deductibles, copayments, and coinsurance. 28 Thus, persistent racial disparities observed in the non-Medicaid group could be a result of differences in patient willingness to pay out-of-pocket costs for health care services such as cancer screening.
Although increased access to Medicaid could act to reduce the disparities observed among patients with CaP, as suggested by the above relationship noted between insurance status and race, the results of the current study indicate that outcomes also are equally worse among men with Medicaid insurance compared with a nonMedicaid, privately insured cohort. We found that men with Medicaid were more likely to present with metastatic disease when compared with privately insured men among patients with CaP who were aged <65 years, after adjusting for sociodemographics. Among men with localized disease, men with Medicaid were less likely to receive definitive treatment and more likely to die of CaP when compared with privately insured men, after adjusting for sociodemographics and known CaP prognostic factors. Moreover, insurance with Medicaid is increasingly found among patients with cancer versus private insurance, and this trend is similar among men diagnosed with CaP. Because men with Medicaid are more likely to have other societal factors that may influence health outcomes, this finding of worse outcomes compared with private insurance should not be taken as a judgment regarding the efficacy of Medicaid versus private insurance overall. Medicaid recipients generally are poor and have poorer health with comorbidities. This group may have poor health care management because access to health care services may be hindered by barriers such as transportation, getting time off from work, poor health literacy, and mistrust in the health care system. 29 The findings of the current study regarding worse outcomes for Medicaid patients overall also are consistent with the prior literature. 23, [30] [31] [32] Patients with Medicaid also are more likely to present with advanced disease, less likely to receive cancer-directed surgery and/or radiotherapy, and to experience worse survival compared with patients with private insurance. 33, 34 Despite our hypothesis that Medicaid reduces disparities in CaP care, barriers to the full implementation of Medicaid expansion nationally exist. Because ACA expansion efforts provided no guidelines for increasing the number of specialists to meet the increased demand and access to cancer care provided by Medicaid, 16, 18, 35 specialists may face an increased burden of Medicaid patients. In addition, barriers in access to care exist because not all providers accept Medicaid because its reimbursement rates generally are lower than those of private insurers. Compensation incentives chosen by medical practices are strong predictors of the types of new patients they accept, which can have detrimental effects for patients with Medicaid coverage. 36 Regardless of what the barriers for Medicaid expansion may be, if the ACA is repealed and a new health care bill limits the number of individuals insured by Medicaid, this could result in increasing disparate outcomes among those with private insurance as well those who cannot afford private insurance and are not yet eligible for Medicare. Any alternative to the ACA should consider the impact of changes on cancer prevention, detection, treatment, and disparities in the United States.
Potential limitations of the current study should be considered. First, the overall sensitivity for radiotherapy variables in SEER is approximately 80%. 37 Although the sensitivity is high, the specificity also is high, meaning that if radiotherapy was captured in SEER, it most likely was received by the patient. However, if it was not captured in SEER, then we do not know whether it was received by the patient or if it was missed by the registry because many patients are treated outside of hospitals. Second, SEER does not provide information regarding quality of treatment. In addition to the receipt of definitive treatment, the quality of the treatment received is an important metric to consider when examining racial disparities in patterns of care. Third, information provided by SEER regarding insurance coverage does not provide details concerning the insurance plans and periods of coverage that patients have. It is important to note that policies differ across networks, coverage, copay, etc. Thus, we were unable to capture the influence of specific policies on outcomes among patients with CaP. Fourth, the follow-up of the current study was short. The insurance variable was introduced to SEER in 2007, with the most recent data from 2014, for which full information is available. Nevertheless, we were able to detect differences between patients with Medicaid coverage and those with other insurance. Longer follow-up is necessary to determine whether the observed differences will increase with time. Finally, SEER lacks information regarding comorbidity and therefore if Medicaid patients had higher levels of comorbidity, then lower rates of definitive treatment and higher rates of presentation of metastatic disease and PCSM may not have been entirely inappropriate.
More work needs to be done to close the racial gap in CaP outcomes for patients with private insurance. Medicaid appears to provide more racially equal CaP outcomes, although efforts need to be made to improve outcomes overall. Further research regarding the impact of different insurance plans on cancer-related care such as prevention, detection, treatment, and quality of care provided for patients with cancer appears warranted.
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